Literature DB >> 8058618

Synthesis and evaluation of amino analogues of valproic acid.

K R Scott1, S Adesioye, P B Ayuk, I O Edafiogho, D John, P Kodwin, T Maxwell-Irving, J A Moore, J M Nicholson.   

Abstract

Valproic acid, an antiepileptic drug, is extensively metabolized in humans. Two putative metabolites, 2-n-propyl-3-aminopentanoic acid (3-aminovalproic acid, 3-amino-VPA; 2a) and 2-n-propyl-4-aminopentanoic acid (4-amino-valproic acid, 4-amino-VPA; 4a), which may result from the transamination of the respective keto acids 1a and 3a may explain the unusual extended seizure protection elicited by valproic acid. The title compounds were synthesized as their diasteriomeric ethyl esters 2b and 4b and submitted for anticonvulsant evaluation by the Antiepileptic Drug Development Program of the National Institute of Neurological and Communicative Disorders and Stroke. The results verified our hypothesis, as 4b was active in the subcutaneous pentylenetetrazol (scMet) evaluation at 30 mg/kg. Both compounds were highly toxic at 300 mg/kg.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8058618     DOI: 10.1023/a:1018978918921

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  Pharmacokinetics and pharmacodynamics of valproate analogues in rats. I. Spiro[4.6]undecane-2-carboxylic acid.

Authors:  M J Liu; K R Scott; G M Pollack
Journal:  Epilepsia       Date:  1990 Jul-Aug       Impact factor: 5.864

2.  Reye-like syndrome associated with valproic acid therapy.

Authors:  N Gerber; R G Dickinson; R C Harland; R K Lynn; L D Houghton; J I Antonias; J C Schimschock
Journal:  J Pediatr       Date:  1979-07       Impact factor: 4.406

3.  Valproic acid and fatal hepatitis.

Authors:  J F Donat; J A Bocchini; E Gonzalez; R N Schwendimann
Journal:  Neurology       Date:  1979-02       Impact factor: 9.910

4.  Valproate levels in children with epilepsy.

Authors:  R A Minns; J K Brown; D H Blackwood; J K McQueen
Journal:  Lancet       Date:  1982-03-20       Impact factor: 79.321

5.  Valproic acid versus ethosuximide in the treatment of absence seizures.

Authors:  S Sato; B G White; J K Penry; F E Dreifuss; J C Sackellares; H J Kupferberg
Journal:  Neurology       Date:  1982-02       Impact factor: 9.910

Review 6.  Drug therapy: Valproic acid.

Authors:  J Koch-Weser; T R Browne
Journal:  N Engl J Med       Date:  1980-03-20       Impact factor: 91.245

7.  3-alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents.

Authors:  C P Taylor; M G Vartanian; R Andruszkiewicz; R B Silverman
Journal:  Epilepsy Res       Date:  1992-04       Impact factor: 3.045

8.  Identification of valproic acid metabolites in human serum and urine using hexadeuterated valproic acid and gas chromatographic mass spectrometric analysis.

Authors:  A Acheampong; F Abbott; R Burton
Journal:  Biomed Mass Spectrom       Date:  1983-11

9.  Valproic acid and several metabolites: quantitative determination in serum, urine, breast milk and tissues by gas chromatography-mass spectrometry using selected ion monitoring.

Authors:  H Nau; W Wittfoht; H Schäfer; C Jakobs; D Rating; H Helge
Journal:  J Chromatogr       Date:  1981-11-13

Review 10.  Concentration-effect relationships of valproic acid.

Authors:  D W Chadwick
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.